April 1, 2019 / 5:23 AM / 6 months ago

BRIEF-Novartis To Acquire IFM Tre To Develop NLRP3 Antagonist Portfolio

April 1 (Reuters) - Novartis AG:

* NOVARTIS TO ACQUIRE IFM TRE TO DEVELOP FIRST-IN-CLASS NLRP3 ANTAGONIST PORTFOLIO TARGETING INNATE IMMUNE SYSTEM

* ACQUISITION OF IFM THERAPEUTICS SUBSIDIARY GIVES NOVARTIS FULL RIGHTS TO ONE CLINICAL AND TWO PRE-CLINICAL NLRP3 ANTAGONIST PROGRAMS

* NLRP3 INHIBITION OFFERS NOVEL APPROACH TO PREVENTING CHRONIC INFLAMMATION THAT DRIVES SERIOUS DISEASE

* IFM TO RECEIVE $310 MILLION UPFRONT, WITH UP TO $1.265 BILLION IN MILESTONES FOR A TOTAL OF $1.575 BILLION Source text for Eikon: Further company coverage: (Reporting by Riham Alkousaa)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below